213 related articles for article (PubMed ID: 33839004)
1. Biochemical evaluation of intracerebroventricular rhNAGLU-IGF2 enzyme replacement therapy in neonatal mice with Sanfilippo B syndrome.
Kan SH; Elsharkawi I; Le SQ; Prill H; Mangini L; Cooper JD; Lawrence R; Sands MS; Crawford BE; Dickson PI
Mol Genet Metab; 2021 Jun; 133(2):185-192. PubMed ID: 33839004
[TBL] [Abstract][Full Text] [Related]
2. BMN 250, a fusion of lysosomal alpha-N-acetylglucosaminidase with IGF2, exhibits different patterns of cellular uptake into critical cell types of Sanfilippo syndrome B disease pathogenesis.
Yogalingam G; Luu AR; Prill H; Lo MJ; Yip B; Holtzinger J; Christianson T; Aoyagi-Scharber M; Lawrence R; Crawford BE; LeBowitz JH
PLoS One; 2019; 14(1):e0207836. PubMed ID: 30657762
[TBL] [Abstract][Full Text] [Related]
3. Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB.
Kan SH; Aoyagi-Scharber M; Le SQ; Vincelette J; Ohmi K; Bullens S; Wendt DJ; Christianson TM; Tiger PM; Brown JR; Lawrence R; Yip BK; Holtzinger J; Bagri A; Crippen-Harmon D; Vondrak KN; Chen Z; Hague CM; Woloszynek JC; Cheung DS; Webster KA; Adintori EG; Lo MJ; Wong W; Fitzpatrick PA; LeBowitz JH; Crawford BE; Bunting S; Dickson PI; Neufeld EF
Proc Natl Acad Sci U S A; 2014 Oct; 111(41):14870-5. PubMed ID: 25267636
[TBL] [Abstract][Full Text] [Related]
4. Translational studies of intravenous and intracerebroventricular routes of administration for CNS cellular biodistribution for BMN 250, an enzyme replacement therapy for the treatment of Sanfilippo type B.
Grover A; Crippen-Harmon D; Nave L; Vincelette J; Wait JCM; Melton AC; Lawrence R; Brown JR; Webster KA; Yip BK; Baridon B; Vitelli C; Rigney S; Christianson TM; Tiger PMN; Lo MJ; Holtzinger J; Shaywitz AJ; Crawford BE; Fitzpatrick PA; LeBowitz JH; Bullens S; Aoyagi-Scharber M; Bunting S; O'Neill CA; Pinkstaff J; Bagri A
Drug Deliv Transl Res; 2020 Apr; 10(2):425-439. PubMed ID: 31942701
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor II peptide fusion enables uptake and lysosomal delivery of α-N-acetylglucosaminidase to mucopolysaccharidosis type IIIB fibroblasts.
Kan SH; Troitskaya LA; Sinow CS; Haitz K; Todd AK; Di Stefano A; Le SQ; Dickson PI; Tippin BL
Biochem J; 2014 Mar; 458(2):281-9. PubMed ID: 24266751
[TBL] [Abstract][Full Text] [Related]
6. Tralesinidase Alfa Enzyme Replacement Therapy Prevents Disease Manifestations in a Canine Model of Mucopolysaccharidosis Type IIIB.
Ellinwood NM; Valentine BN; Hess AS; Jens JK; Snella EM; Jamil M; Hostetter SJ; Jeffery ND; Smith JD; Millman ST; Parsons RL; Butt MT; Chandra S; Egeland MT; Assis AB; Nelvagal HR; Cooper JD; Nestrasil I; Mueller BA; Labounek R; Paulson A; Prill H; Liu XY; Zhou H; Lawrence R; Crawford BE; Grover A; Cherala G; Melton AC; Cherukuri A; Vuillemenot BR; Wait JCM; O'Neill CA; Pinkstaff J; Kovalchin J; Zanelli E; McCullagh E
J Pharmacol Exp Ther; 2022 Sep; 382(3):277-286. PubMed ID: 35717448
[TBL] [Abstract][Full Text] [Related]
7. Safety, pharmacokinetics and CNS distribution of tralesinidase alfa administered via intracerebroventricular infusion to juvenile cynomolgus monkeys.
Pinkstaff J; McCullagh E; Grover A; Melton AC; Cherukuri A; Wait JC; Nguyen A; Butt MT; Trombley JL; Reed RP; Adams EL; Boyd RB; Chandra S; Henshaw J; O'Neill CA; Zanelli E; Kovalchin J
Toxicol Rep; 2023; 10():357-366. PubMed ID: 36923444
[TBL] [Abstract][Full Text] [Related]
8. Short-term enzyme replacement in the murine model of Sanfilippo syndrome type B.
Yu WH; Zhao KW; Ryazantsev S; Rozengurt N; Neufeld EF
Mol Genet Metab; 2000 Dec; 71(4):573-80. PubMed ID: 11136549
[TBL] [Abstract][Full Text] [Related]
9. Clearance of Heparan Sulfate and Attenuation of CNS Pathology by Intracerebroventricular BMN 250 in Sanfilippo Type B Mice.
Aoyagi-Scharber M; Crippen-Harmon D; Lawrence R; Vincelette J; Yogalingam G; Prill H; Yip BK; Baridon B; Vitelli C; Lee A; Gorostiza O; Adintori EG; Minto WC; Van Vleet JL; Yates B; Rigney S; Christianson TM; Tiger PMN; Lo MJ; Holtzinger J; Fitzpatrick PA; LeBowitz JH; Bullens S; Crawford BE; Bunting S
Mol Ther Methods Clin Dev; 2017 Sep; 6():43-53. PubMed ID: 28664165
[TBL] [Abstract][Full Text] [Related]
10. Differential Uptake of NAGLU-IGF2 and Unmodified NAGLU in Cellular Models of Sanfilippo Syndrome Type B.
Prill H; Luu A; Yip B; Holtzinger J; Lo MJ; Christianson TM; Yogalingam G; Aoyagi-Scharber M; LeBowitz JH; Crawford BE; Lawrence R
Mol Ther Methods Clin Dev; 2019 Sep; 14():56-63. PubMed ID: 31309128
[TBL] [Abstract][Full Text] [Related]
11. Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum.
Cressant A; Desmaris N; Verot L; Bréjot T; Froissart R; Vanier MT; Maire I; Heard JM
J Neurosci; 2004 Nov; 24(45):10229-39. PubMed ID: 15537895
[TBL] [Abstract][Full Text] [Related]
12. Disease correction in mucopolysaccharidosis type IIIB mice by intraparenchymal or cisternal delivery of a capsid modified AAV8 codon-optimized NAGLU vector.
Rouse CJ; Hawkins K; Kabbej N; Dalugdug J; Kunta A; Kim MJ; Someya S; Herbst Z; Gelb M; Dinelli I; Butterworth E; Falk DJ; Rosenkrantz E; Elmohd H; Khaledi H; Mowafy S; Ashby F; Heldermon CD
Hum Mol Genet; 2023 Jan; 32(3):417-430. PubMed ID: 35997776
[TBL] [Abstract][Full Text] [Related]
13. Enzyme Replacement Therapy for Mucopolysaccharidosis IIID using Recombinant Human α-
Wang F; Moen DR; Sauni C; Kan SH; Li S; Le SQ; Lomenick B; Zhang X; Ekins S; Singamsetty S; Wood J; Dickson PI; Chou TF
Mol Pharm; 2021 Jan; 18(1):214-227. PubMed ID: 33320673
[TBL] [Abstract][Full Text] [Related]
14. A model of mucopolysaccharidosis IIIB (Sanfilippo syndrome type IIIB): N-acetyl-alpha-D-glucosaminidase deficiency in Schipperke dogs.
Ellinwood NM; Wang P; Skeen T; Sharp NJ; Cesta M; Decker S; Edwards NJ; Bublot I; Thompson JN; Bush W; Hardam E; Haskins ME; Giger U
J Inherit Metab Dis; 2003; 26(5):489-504. PubMed ID: 14518829
[TBL] [Abstract][Full Text] [Related]
15. Intravenous administration of human umbilical cord blood cells in an animal model of MPS III B.
Garbuzova-Davis S; Klasko SK; Sanberg PR
J Comp Neurol; 2009 Jul; 515(1):93-101. PubMed ID: 19399896
[TBL] [Abstract][Full Text] [Related]
16. Residual N-acetyl-α-glucosaminidase activity in fibroblasts correlates with disease severity in patients with mucopolysaccharidosis type IIIB.
Meijer OLM; Welling L; Valstar MJ; Hoefsloot LH; Brüggenwirth HT; van der Ploeg AT; Ruijter GJG; Wagemans T; Wijburg FA; van Vlies N
J Inherit Metab Dis; 2016 May; 39(3):437-445. PubMed ID: 26907177
[TBL] [Abstract][Full Text] [Related]
17. Retrovirally transduced bone marrow has a therapeutic effect on brain in the mouse model of mucopolysaccharidosis IIIB.
Zheng Y; Ryazantsev S; Ohmi K; Zhao HZ; Rozengurt N; Kohn DB; Neufeld EF
Mol Genet Metab; 2004 Aug; 82(4):286-95. PubMed ID: 15308126
[TBL] [Abstract][Full Text] [Related]
18. Disease modeling for Mucopolysaccharidosis type IIIB using patient derived induced pluripotent stem cells.
Huang W; Cheng YS; Yang S; Swaroop M; Xu M; Huang W; Zheng W
Exp Cell Res; 2021 Oct; 407(1):112785. PubMed ID: 34411609
[TBL] [Abstract][Full Text] [Related]
19. Mouse model of Sanfilippo syndrome type B: relation of phenotypic features to background strain.
Gografe SI; Garbuzova-Davis S; Willing AE; Haas K; Chamizo W; Sanberg PR
Comp Med; 2003 Dec; 53(6):622-32. PubMed ID: 14727810
[TBL] [Abstract][Full Text] [Related]
20. Molecular basis of mucopolysaccharidosis type IIIB in emu (Dromaius novaehollandiae): an avian model of Sanfilippo syndrome type B.
Aronovich EL; Johnston JM; Wang P; Giger U; Whitley CB
Genomics; 2001 Jun; 74(3):299-305. PubMed ID: 11414757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
